Back to results
US 2023/0266328 A1Published application
Multiomic analysis of nanoparticle-coronas
AssigneeThe University of Manchester
InventorsMarilena HADJIDEMETRIOU, Kostas KOSTARELOS, Lois GARDNER, Lana PAPAFILIPPOU
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for simultaneously identifying and/or detecting distinct classes of biomarker in biofluid samples, such as blood.
Claims25
A method of identifying biomarkers from two or more distinct biomolecule classes in a biofluid, wherein the method comprises:
- (a) contacting a plurality of nanoparticles with a biofluid to allow a biomolecule corona to form on the surface of said nanoparticles;
- (b) isolating the nanoparticles and surface-bound biomolecule corona;
- and
- (c) analyzing the biomolecule corona to identify biomarkers from two or more distinct biomarker classes.
1 more element
(canceled)
(canceled)
(canceled)
(canceled)
A method for detecting a disease state in a subject, comprising:
- (a) contacting a biofluid sample from the subject with a plurality of nanoparticles under conditions to allow a biomolecule corona to form on the surface of said nanoparticles;
- and
- (b) analyzing the biomolecule corona for one or more disease-specific biomarkers from two or more biomolecule classes, which is determinative of the presence of a disease in said subject.
A method for monitoring cancer progression in a subject, comprising:
- (a) contacting a biofluid sample from the subject with a plurality of nanoparticles under conditions to allow a biomolecule corona to form on the surface of said nanoparticles;
- and
- (b) analyzing the biomolecule corona for one or more cancer-specific biomarkers from two or more biomolecule classes;
- wherein the degree of cancer progression is determined based on the level of the cancer-specific biomarker(s) relative to a reference amount;
- optionally wherein the cancer is selected from the group consisting of:
- ovarian, lung, prostate, melanoma and blood cancer, including leukemia, lymphoma and myeloma.
3 more elements
(canceled)
Dependencies are inferred from the claim text.